These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6509455)

  • 21. Phase II trial of mitoxantrone.
    Anderson KC; Cohen GI; Garnick MB
    Cancer Treat Rep; 1982 Nov; 66(11):1929-31. PubMed ID: 7139638
    [No Abstract]   [Full Text] [Related]  

  • 22. Mitoxantrone and advanced squamous cell carcinoma of the cervix: a Southwest Oncology Group Study.
    Hilgers RD; Von Hoff DD; Stephens RL; Boutselis JG
    Cancer Treat Rep; 1986 Apr; 70(4):527-8. PubMed ID: 3698047
    [No Abstract]   [Full Text] [Related]  

  • 23. Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer.
    Creech RH; Catalano RB; Dierks KM; Shah MK
    Cancer Treat Rep; 1984 Dec; 68(12):1499-501. PubMed ID: 6548936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II evaluation of vindesine in patients with advanced breast cancer.
    Currie VE; Camacho F; Wittes R; Young C
    Cancer Treat Rep; 1980; 64(4-5):693-95. PubMed ID: 7427954
    [No Abstract]   [Full Text] [Related]  

  • 25. Mitoxantrone and cyclophosphamide in patients with advanced breast cancer.
    Ehninger G; Weible KH; Heidemann EG; Waller HD
    Cancer Treat Rep; 1984 Oct; 68(10):1283-4. PubMed ID: 6525600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of chlorozotocin in advanced breast cancer.
    Edmonson JH; Green SJ; Ingle JN; Ahmann DL; Disel HF; Creagan ET
    Cancer Treat Rep; 1981; 65(5-6):537-8. PubMed ID: 6453648
    [No Abstract]   [Full Text] [Related]  

  • 27. Mitoxantrone: a promising new chemotherapeutic agent.
    Dalton WS; Alberts DS
    Ariz Med; 1984 Feb; 41(2):96-8. PubMed ID: 6703919
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
    Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
    Am J Clin Oncol; 1983 Feb; 6(1):45-8. PubMed ID: 6837506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II evaluation of mitoxantrone in patients with bronchogenic carcinoma: a Southeastern Cancer Study Group trial.
    Kramer BS; Gams R; Birch R; Einhorn L; Buchanan R
    Cancer Treat Rep; 1984 Oct; 68(10):1295-6. PubMed ID: 6525601
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study.
    Ettinger DS; Finkelstein DM; Harper GR; Ruckdeschel JC; Chang AY; Camacho FJ; Marsh JC; Silber R; Wolter JM
    Cancer Treat Rep; 1985 Sep; 69(9):1033-4. PubMed ID: 3861248
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
    Tominaga T; Kitamura M; Hayashi K; Takahashi I; Kosaki G
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1669-74. PubMed ID: 6591857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group.
    Knight WA; Von Hoff DD; Neidhart JA; Tranum BL; Fabian C; Jones SE
    Invest New Drugs; 1983; 1(2):181-4. PubMed ID: 6678866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of mitoxantrone in refractory germ cell tumors: a trial of the Southeastern Cancer Study Group.
    Williams SD; Birch R; Gams R; Irwin L
    Cancer Treat Rep; 1985 Dec; 69(12):1455-6. PubMed ID: 3000593
    [No Abstract]   [Full Text] [Related]  

  • 34. Growth and ultrastructural responses of T-47D human breast tumor cells to treatment with mitoxantrone.
    Safa AR; Ballou RJ; Tseng MT
    Cancer Detect Prev; 1985; 8(4):455-64. PubMed ID: 4053107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial.
    Gockerman JP; Raney M; Logan T
    Cancer Treat Rep; 1985 Sep; 69(9):1029-30. PubMed ID: 3861247
    [No Abstract]   [Full Text] [Related]  

  • 36. Weekly mitoxantrone in the treatment of advanced pancreatic carcinoma: a Southeastern Cancer Study Group Trial.
    DeSimone PA; Gams R; Bartolucci A
    Cancer Treat Rep; 1986 Jul; 70(7):929-30. PubMed ID: 3521850
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study.
    Eisenhauer EA; Evans WK; Raghavan D; Desmeules MJ; Murray NR; Stuart-Harris R; Wilson KS
    Cancer Treat Rep; 1986 Aug; 70(8):1029-30. PubMed ID: 3731150
    [No Abstract]   [Full Text] [Related]  

  • 38. Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies.
    Sledge GW
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):57-9. PubMed ID: 8893901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
    Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
    Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Phase II study of mitoxantrone for hematologic malignancies].
    Ueoka H; Ueno K; Yamane T; Toyoda K; Endo H; Nishihara R; Takahashi I; Ohnoshi T; Kitajima K; Kimura I
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2399-402. PubMed ID: 6639101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.